a little bit of cut and paste with the old word processor, and...... voila!!
er.............
Sunday June 24, 8:37 pm Eastern Time
Press Release
SOURCE: 3-Dimensional Pharmaceuticals, Inc.
3-Dimensional Pharmaceuticals, Inc. to Present at JP
Morgan H&Q 19th Annual Healthcare Conference
With Simultaneous Webcast
EXTON, Penn., June 24 /PRNewswire/ -- 3-Dimensional Pharmaceuticals, Inc. (Nasdaq:
DDDP - news) today announced that David C. U'Prichard, Ph.D., Chief Executive Officer,
will present at 2:15 PM Pacific, June 25, 2001 to the BIO 2001 International Investor
Forum in San Diego.
Dr. U'Prichard's presentation will include an overview of 3DP's leading-edge drug discovery
technology platform for small molecules, and will provide details on 3DP's business model,
which features a dual approach of using its technology in third-party collaborations in
addition to building 3DP's own drug pipeline. Dr. U'Prichard will discuss progress with
3DP's internal R&D program, discovery alliances and licensing agreements, and will review
company objectives for the remainder of 2001.
3DP's presentation will be webcast live at
informedinvestors.com .
3-Dimensional Pharmaceuticals, Inc. (http://www.3dp.com) is a post-genomics drug
discovery company dedicated to revolutionizing small-molecule discovery. 3DP has
developed and integrated a set of proprietary technologies called DiscoverWorks(TM),
which accelerates and improves the drug discovery process and capitalizes on opportunities
arising from human genome sequencing. 3DP technologies can be applied to virtually any
disease target, and can produce compounds suitable for drug development in a more timely
and cost-effective manner and with a higher probability of success than conventional
methods. 3DP is using its technologies both to assist collaborators in discovering drug
candidates, and to discover and develop its own drug candidates.
Statements in this press release that are not strictly historical are ``forward-looking''
statements which involve a high degree of risk and uncertainty. Such statements are only
predictions, and the actual events or results may differ materially from those projected in such
forward-looking statements. Factors that could cause or contribute to differences include,
but are not limited to, risks associated with clinical trials and product development, the long
and arduous process of obtaining regulatory approvals, protection and enforcement of
relevant patents and proprietary rights, and development and availability of competitive products or technologies. Certain of
these factors and others are more fully described in the Company's Registration Statement on Form S-1, as filed with the
Securities and Exchange Commission.
SOURCE: 3-Dimensional Pharmaceuticals, Inc. |
